Lowest Price Guaranteed
Pages
135
Last Updated
December 2025
View Count
13087
The global sterile injectable contract manufacturing market is expected to grow from USD 14.4 billion in 2024 to USD 33.7 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 8% during the forecast period.
 |
To learn more about this report, request a free sample copy
injectables refer to the form of medication and therapeutic drugs that are directly administered into the bloodstream or tissue of the body. Unlike oral therapeutic drugs, sterile injectables have the ability to bypass the innate defense mechanism of the body, ensuring higher efficacy of the therapeutic drugs. The growing shift towards cell and gene therapy has surged the demand for sterile injectables that deliver the drugs at targeted sites. Several promising benefits such as fast drug action, quick drug absorption, elimination of drug degradation risk, and low requirement of drug support the high demand for sterile injectables. Sterile injectables require specialized manufacturing units and advanced technological support to maintain a sterile environment for the production of these products.
Further, there is a risk of contamination in sterile injectables when manufactured with the conventional approach, and pharmaceutical companies often face challenges in compilation with regulatory challenges. In addition, the high cost associated with the installation of complex manufacturing platforms and recruiting skilled personnel has caught the attention of pharmaceutical players towards sterile injectables contract manufacturing services providers. Contract manufacturing organizations (CMOs) provide state-of-the-art facilities and tech-driven infrastructure and adhere to the regulatory standards for efficiency, safety as well as quality. Furthermore, sterile injectables contract manufacturers also provide support to skilled personnel who have expertise in advanced technologies required for the development of these products.
Sterile injectables contract manufacturing services offer several advantages, such as operational efficiency, cost reduction, quality control, and adherence to regulatory guidelines. The significances offered by the CMOs accelerate the development of sterile injectables, thereby bridging the gap between manufacturing and market supply. Driven by the increase in the adoption of contract manufacturing services, various market players enter into strategic collaborations, mergers, partnerships, and acquisitions that further result in market expansion. For instance, In May 2024, Sharp (leading provider of pharmaceutical packaging and clinical trial supply services) expanded its Macungie Pennsylvania Plant, aiming to enhance production capabilities for sterile injectables secondary packaging. In February 2024, Simtra BioPharma Solution announced an investment of over USD 250 million for the expansion of its sterile fill / finish manufacturing campus in Bloomington. The expansion also followed Warburg Pincus’s and Advent International’s acquisition of Baxter’s BioPharma Solution in October 2023 - this will now operate under Simtra Biopharma Solutions. The rising interest of key players in this field and ongoing acquisition as well as investments will drive the sterile injectable contract manufacturing market growth during the forecast period.
 |
 |
 |
The market report covers a comprehensive analysis of leading companies that are engaged in this market across different segments, as defined in the table below:
| Key Report Attributes | Details | |
| Historical Trend | Since 2019 | |
| Time Period | 15 Years | |
| Future Trend | Till 2035 | |
| Market Size 2035 | USD 33.7 billion | |
| Market CAGR | ~8% | |
| By Molecules Type |
|
|
| By Therapeutic Applications |
|
|
| Route of Administration |
|
|
| Distribution by End Users |
|
|
| Key Geographical Regions |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
The primary objective of the sterile injectable contract manufacturing market report is to provide a comprehensive analysis of market size, trends, share, growth opportunities, and future forecast. We have provided an informed estimate of the market outlook and the evolution of the market till 2035. In addition, we have segmented future opportunities across various segments including type of molecules (small molecules and large molecules, therapeutic application (cancer, diabetes, cardiovascular disease, neurological disorders, infectious disorders, musculoskeletal and others), route of administration (subcutaneous, intravenous, intramuscular and others), end user (pharmaceutical companies, biopharmaceutical companies and others) and global regions (North America, Europe, Asia-Pacific, and the rest of the world).
To account for the uncertainties associated with the sterile injectable contract manufacturing market and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base, and optimistic tracks of the market's evolution.
 |
 |
 |
Based on the type of molecule, the sterile injectable contract manufacturing market is segmented into small molecules and large molecules. According to our projection, large molecules currently account for the largest share (62%) of the market. This can be attributed to the fact that large molecules require advanced manufacturing processes such as cell culturing and recombinant DNA technology. Furthermore, the manufacturing of large molecules requires skilled personnels who can handle complex processes effortlessly. Hence, growing investment in sterile injectables contract manufacturing organizations for the production of large molecules is the primary reason for the highest share. It is worth highlighting here that the trend of growth is likely to remain unchanged during the forecast period owing to the growing demand for large molecules for the development of cell and gene therapy that are often delivered as sterile injectables. These advanced therapies contain sensitive biologics material that are required to deliver directly into the blood stream or tissues. Therefore, the growing number of cell and gene therapies has underscored the required of sterile injectable solutions to deliver these therapeutics with higher efficacy and safety.
Based on therapeutic applications, the sterile injectable contract manufacturing market is segmented into cancer, diabetes, cardiovascular disease, neurological disorders, infectious disorders, musculoskeletal and others. Currently, cancer occupies 29.20% share of the market. The highest share is majorly due to the growing pipeline of gene-based therapies for the treatment of cancer. It is worth noting here that cancer therapeutics have complex biologics formulation that required specialized sterile injectable formulations to deliver on targeted sites, which is anticipated to surge the requirement of sterile injectable solutions. Furthermore, the growing approval of anti-cancer therapeutics and rising R&D process for the development of advance drugs are some of the crucial factors of highest growth share of cancer in this market. However, in the long run, neurological disorders estimated to show lucrative growth potential during the forecast period owing to the increasing clinical research on therapeutic drugs for the treatment of neurological disorders such as Alzheimer’s disease and Parkinson’s disease.
Based on the route of administration, the market is segmented into subcutaneous, intravenous, intramuscular and others. According to our projection, intravenous currently accounts for the highest (32.6%) sterile injectable contract manufacturing market share. This can be attributed to the growing approval for sterile injectables for administration via intravenous routes. Furthermore, intravenous route allows delivery of precise dosage in controlled manner at targeted sites, making it a preferable choice for drug delivery during emergencies. However, in the long run, the subcutaneous route of administration is estimated to grow at a higher CAGR during the forecast period.
Based on the type of end users, the sterile injectables market is segmented into pharmaceutical companies, biopharmaceutical companies and others. According to our projection, biopharmaceutical companies currently occupy 46% of the overall revenue share. The growth can be attributed to the increasing preferences of outsourcing services for the production of biologics to treat diseases. It is worth noting here that the trend is likely to remain unchanged during the forecast period driven by the growing pipeline of biologics in clinical studies.
Based on the key geographical region, the global sterile injectables contract manufacturing market is distributed into North America, Europe, Asia-Pacific and the rest of the world. According to our market study, North America currently holds 36.6% of the overall revenue share of the market. The highest growth share can be attributed to the increasing preferences of outsourcing manufacturing services to contract manufacturers in this region. Additionally, complex stringent regulatory guidelines associated with manufacturing and approval of drugs are estimated to promote the contract manufacturing of sterile injectables in this region. It is worth highlighting here that sterile injectables contract manufacturing market in Asia-Pacific is likely to grow at a higher CAGR during the forecast period.
 |
 |
 |
The Global Sterile Injectable Contract Manufacturing Market: Industry Trends and Future Forecast, Till 2035, market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the handheld ultrasound scanners market. The market research report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in the market.
Several market drivers that are propelling the growth in this field include a growing pipeline of biologics and sterile injectable drugs. Driven by the growing risk of chronic diseases, several pharmaceutical companies are driving their focus on the development of target-specific or injectable drugs owing to the significance offered, such as precise dosing, faster onset of action, and patient adherence. Further, the global pipeline of specialized therapies, including gene therapies and sterile injectable drugs, is increasing continuously to target a range of therapeutic areas, including autoimmune diseases, diabetes, and oncology, that contributed towards the growth of contract manufacturing of sterile injectables. The ongoing demand for injectable drugs and faster drug approval have encouraged biopharmaceutical companies to leverage contract manufacturing while adhering to regulatory requirements.
Contract manufacturing organizations offer several advantages, such as technological support, operational efficiency, regulatory guidelines support, and commercialization processing. By partnering with sterile injectables contract manufacturing services providers, pharmaceutical companies can get technology support and state-of-the-art facilities and reduce operational time as well as cost. Moreover, partnering with contract manufacturers improves efficiency and ensures a focus on drug research activities. Driven by the significance offered by the contract manufacturers, there has been a strategic increase in the adoption rate of sterile injectables contract manufacturing services, which is anticipated to drive growth in this market.
Some of the significant market restraints that may impede its growth during the upcoming years include high capital investment, stringent regulations, approval delays, and technological complexities. The development of sterile injectables is subjected to compilation with stringent regulatory guidelines provided by agencies such as the FDA and EMA. Compliance with regulatory guidelines requires significant documents, quality assurance test reports, and validations that result in approval delays. Further, the high initial investment and maintenance cost of advanced equipment and technology to ensure sterile manufacturing conditions is a major challenge for contract manufacturing services providers.
Rising investment, strategic collaborations, and partnerships between key players are projected to boost the growth in the sterile injectables contract manufacturing market. For instance, in May 2024, Maiva Pharma (a leading sterile injectables manufacturer) secured INR 1000 crore or 10 million from primary and secondary funding led by InvAscent and managed by Morgan Stanely Private Equity Asia and India Life Sciences Fund IV. The investment has been raised to increase its capacity to form sterile dosage forms, including prefilled syringes and hormone injectables. Furthermore, in April 2024, Eli Lilly acquired Nexus Pharmaceuticals Pleasant Prairie, WI manufacturing facility. The strategic acquisition deal has been done to enhance the injectables product manufacturing network. Further, the acquisition of a state-of-the-art facility emphasizes the commitment to innovation in injectable drugs. Production at this newly acquired platform would be commencing by the end of 2025. Driven by the ongoing investments and collaborations in the industry, it has given a new ray to the top investors and stakeholders active in this industry to drive innovations and expand their platform capacity to meet the growing demand for injectable drugs.
Examples of the leading companies engaged in this industry (the complete list of key players has also been listed in the detailed report) include Aenova Group, Baxter, Boehringer Ingelheim, Catalent, Cipla, Fresenius Kabi, Famar, Grifols, NextPharma Technologies, Recipharm, Unither Pharmaceuticals and Vetter Pharma.
This market report includes an easily searchable excel database of all the companies providing sterile injectable solutions, worldwide.